Jichuan Pharmaceutical Co., Ltd. approved production of prulifloxacin

According to the information of the State Food and Drug Administration (CFDA), the evaluation status of pulifloxacin dispersible tablets, a generic drug of Jichuan Pharmaceutical Co., Ltd., has changed to "certificate preparation completed - approved document issued in Jiangsu Province" The relevant person in charge of the company confirmed that the drug has been approved for production and "will send someone to the Provincial Bureau to collect the product" Prulifloxacin is the representative of the latest generation of quinolones and the only precursor drug in quinolones family Prulifloxacin has three advantages: improving the bioavailability of the drug, enhancing the targeting, reducing the toxicity and side effects of the drug In China, only Jiangsu Yabang Epson Pharmaceutical Co., Ltd (commodity name is wanfile) has the pulifloxacin dispersible tablet type, but there are not a few tablet manufacturers of the drug, including many enterprises such as Beijing New Pharmaceutical Co., Ltd., Kangyuan Pharmaceutical Co., Ltd., Luoxin Pharmaceutical Co., Ltd., Kelun Pharmaceutical Co., Ltd At present, Jichuan Pharmaceutical Co., Ltd has successfully listed its backdoor Hongcheng Co., Ltd., which has advantages in pediatrics, digestion, anti infection and other fields The sales revenue of Pudilan oral liquid, the leading product, reached 761 million yuan in 2012, up 46% year on year However, industry insiders said that although Jichuan pharmaceutical has channel advantages in anti infective drugs, the market share of quinolones has declined significantly since the anti infective order was limited, "there is a certain challenge for this variety to be made."